This is a working overview of freeze-thaw cycle, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== History == Inotuzumab ozogamicin was discovered by scientists collaborating at Celltech and Wyeth, and it was developed by Pfizer which had acquired Wyeth. Celltech and Wyeth entered into a collaboration in 1991 to develop antibody-drug conjugates. The humanized antibody portion was generated at Celltech and the DNA encoding it was transfected into CHO cells, which were sent to Wyeth, where chemists expressed and purified the antibodies and conjugated them with the linker to the cytotoxin; the work was published in 2004. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In May 2013, a phase III trial in participants with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility. In March 2024, the FDA approved inotuzumab ozogamicin for the treatment of children aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Efficacy was evaluated in a multicenter, single-arm, open-label study in 53 pediatric participants aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. Two dose levels were evaluated--an initial dose of 1.4 mg/m2/cycle in 12 participants and 1.8 mg/m2/cycle in 41 participants. Premedications included methylprednisolone 1 mg/kg (maximum of 50 mg), an antipyretic, and an antihistamine. Participants received a median of 2 cycles of therapy (range: 1 to 4 cycles).
== In vivo activity == NR58-3.14.3 also inhibits the recruitment of leukocytes (macrophages, T cells, B cells) due to the chemokine CCL2 in rat skin. A similar effect was observed using Lipopolysaccharide (LPS) instead of CCL2 (macrophages, neutrophils, T cells, B cells). In addition NR58-3.14.3 inhibits LPS-induced accumulation of tumour necrosis factor-α (TNF-α). This is consistent with the peptide acting as a chemokine inhibitor up-steam of TNF-α productsion and anti-inflammatory in vivo. The cyclic peptide NR58-3.14.3 was shown to be a powerful anti-inflammatory agent in vivo inhibiting inflammation in a number of disease models such as atherosclerosis, ischemia, lung disease, surgical adhesions, endometriosis and pulmonary graft-versus-host disease. It has been suggested that blockage of chemokine function using these molecules should not have a detrimental toxicological effect.
==== Musée d'histoire naturelle (Museum of Natural History) ==== Founded in 1881 but heavily damaged during World War II, the Museum of Natural History is housed in Le Havre's former law courts, built in the mid-18th century; the façade and monumental staircase are listed as historical monuments. The museum houses mineralogy, zoology, ornithology, palaeontology and prehistory departments as well as 8,000 early 19th-century paintings from the collection of local naturalist and traveller Charles-Alexandre Lesueur (1778–1846). The museum was destroyed during Allied bombings on 5 September 1944. The library was lost, along with its collections of photographs, scientific instruments and archives. The mineral and geological collections were all destroyed, including a rare collection of local mineral specimens of Normandy. The destruction of the museum was so intense, that all the catalogues, lists of donations, lists of purchases and other archives prevented even a precise inventory of all that was lost."
signaling PRRs that activate gene transcriptional mechanisms that lead to cellular activation, endocytic PRRs that function in pathogen binding and phagocytosis, and secreted PRRs that usually function as opsonins or activators of complement. The recognition and clearance of invading microorganisms occurs through both opsonin-dependent and opsonin–independent pathways. The molecular mechanisms facilitating opsonin-dependent phagocytosis are different for specific opsonin/receptor pairs. For example, phagocytosis of IgG-opsonized pathogens occurs through the Fcγ receptors (FcγR), and involves phagocyte extensions around the microbe, resulting in the production of pro-inflammatory mediators. Conversely, complement receptor-mediated pathogen ingestion occurs without observable membrane extensions (particles just sink into the cell) and does not generally results in an inflammatory mediator response. Following internalization, the microbe is enclosed in a vesicular phagosome which then undergoes fusion with primary or secondary lysosomes, forming a phagolysosome. There are various mechanisms that lead to intracellular killing; there are oxidative processes, and others independent of the oxidative metabolism. The former involves the activation of membrane enzyme systems that lead to a stimulation of oxygen uptake (known as the respiratory burst), and its reduction to reactive oxygen intermediates (ROIs), molecular species that are highly toxic for microorganisms.
=== Elimination === Small amounts of metabolites (alpha-methyldopa and alpha-methyldopamine) were found after the administration of both single-doses and maintenance-doses of AMPT. Small amounts of methyltyramine and alpha-methylnoradrenaline were found in patients undergoing AMPT therapy. Urine analysis also recovered 45 to 88 percent of unchanged AMPT after drug ingestion. Of the total AMPT excreted, 50 to 60 percent appeared in urine within the first 8 hours and 80 to 90 percent appeared within 24 hours of oral administration.
Sources: en.wikipedia.org
The active components of an RNA-induced silencing complex (RISC) are endonucleases called Argonaute proteins, which cleave the target mRNA strand complementary to their bound siRNA. As the fragments produced by Dicer are double-stranded, they could each in theory produce a functional siRNA. However, only one of the two strands, which is known as the guide strand, binds Argonaute and directs gene silencing. The other anti-guide strand or passenger strand is degraded during RISC activation. Although it was first believed that an ATP-dependent helicase separated these two strands, the process proved to be ATP-independent and performed directly by the protein components of RISC. However, an in vitro kinetic analysis of RNAi in the presence and absence of ATP showed that ATP may be required to unwind and remove the cleaved mRNA strand from the RISC complex after catalysis. The guide strand tends to be the one whose 5′ end is less stably paired to its complement, but strand selection is unaffected by the direction in which Dicer cleaves the dsRNA before RISC incorporation. Instead, the R2D2 protein may serve as the differentiating factor by binding the more-stable 5′ end of the passenger strand. The structural basis for binding of RNA to the Argonaute protein was examined by X-ray crystallography of the binding domain of an RNA-bound Argonaute.
== Hormone and metabolic modulators == Hormone levels of a particular hormone, like testosterone, can be changed not only by administering it, but also by altering related hormones. For example, the estrogens estrone and estradiol are biosynthetically produced by the enzyme aromatase, respectively, from androstenedione and testosterone, which are both produced from 17α-hydroxyprogesterone. Thus, when the body senses low levels of estrogen, the precursor compounds 17α-hydroxyprogesterone, androstenedione, and testosterone are up-regulated. Likewise, interfering with a hormone's receptor leads to similar effects. Because of these natural hormone-hormone interdependent biosynthetic pathways and hormone-receptor interactions, all aromatase inhibitors, including anastrozole, letrozole, aminoglutethimide, exemestane, formestane, and testolactone are banned. Selective estrogen receptor modulators, including raloxifene, tamoxifen and toremifene are banned. Clomiphene, cyclofenil, fulvestrant, and all other anti-estrogenic substances are banned. Myostatin inhibitors are banned. Metabolic modulators including peroxisome proliferator-activated receptor delta (PPARδ) agonists (e.g., GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are also banned. Meldonium was banned on 1 January 2016, which was often used during the Russian doping scandal.
=== Committee === WOSM's committee is its executive governing body, composed of elected volunteers and its secretary general, which is responsible for the implementation of the resolutions of its conference and governs the organization between meetings of its conference. The committee meets at least twice a year. Its steering committee, consisting of the chairperson, two vice-chairpersons and its youth advisor and secretary general meet as needed. The committee has 21 members. Twelve, each from a different country, are elected for three-year terms by WOSM's conference. The members, elected without regard to their nationality, represent the interests of the movement as a whole, not those of their country. The secretary general, the treasurer of WOSM and a representative member of the board of the World Scout Foundation and the chairpersons of the regional Scout committees are ex-officio members of the committee. From 2008 to 2021 six Youth Advisors to the WSC were elected by the World Scout Youth Forum. The Youth Advisors participated in all of the WSC meetings and were also part of the governing structure between the meetings. There will be no Youth Advisors from 2024. The 2021–2024 committee set up work streams to address the top strategic priorities, as defined by WOSM's conference. Task forces include:
=== Other dermatological conditions === In addition to the approved use for treating acne vulgaris, researchers have investigated off-label applications for dermatological conditions, such as rosacea, psoriasis, and other conditions. Rosacea was reported as responding favorably to doses lower than used for acne. Isotretinoin in combination with ultraviolet light was shown affective for treating psoriasis. Isotretinoin in combination with injected interferon-alpha showed some potential for treating genital warts. Isotretinoin in combination with topical fluorouracil or injected interferon-alpha showed some potential for treating precancerous skin lesions and skin cancer.
The War of the Fifth Coalition ended with the Treaty of Schönbrunn (14 October 1809). In the east, only the Tyrolese rebels led by Andreas Hofer continued to fight the French-Bavarian army until finally defeated in November 1809. In the west, the Peninsular War continued. Economic warfare between Britain and France continued: The British continued a naval blockade of French-controlled territory. Due to military shortages and lack of organisation in French territory, many breaches of the Continental System occurred and the French Continental System was largely ineffective and did little economic damage to Great Britain. Both sides entered further conflicts in attempts to enforce their blockade. As Napoleon realised that extensive trade was going through Spain and Russia, he invaded those two countries; the British fought the United States in the War of 1812 (1812–1815). In 1810, the French Empire reached its greatest extent. Napoleon married Marie-Louise, an Austrian Archduchess, with the aim of ensuring a more stable alliance with Austria and of providing the Emperor with an heir (something his first wife, Joséphine, had failed to do). As well as the French Empire, Napoleon controlled the Swiss Confederation, the Confederation of the Rhine, the Duchy of Warsaw and the Kingdom of Italy. Territories allied with the French included:
Sources: en.wikipedia.org
== H == Harmonin b Hrp36 Hexokinase Hrp65-2 Hectochlorin HS1 (actin binding protein) Helicase II Hsp27 HIP1 (Huntingtin Interacting protein 1) Hsp70 Histactophilin Hsp90 Histidine rich protein II Hsp100
== Targets == A "target" is produced within the pharmaceutical industry. Generally, the "target" is the naturally existing cellular or molecular structure involved in the pathology of interest where the drug-in-development is meant to act. However, the distinction between a "new" and "established" target can be made without a full understanding of just what a "target" is. This distinction is typically made by pharmaceutical companies engaged in the discovery and development of therapeutics. In an estimate from 2011, 435 human genome products were identified as therapeutic drug targets of FDA-approved drugs. "Established targets" are those for which there is a good scientific understanding, supported by a lengthy publication history, of both how the target functions in normal physiology and how it is involved in human pathology. This does not imply that the mechanism of action of drugs that are thought to act through a particular established target is fully understood. Rather, "established" relates directly to the amount of background information available on a target, in particular functional information. In general, "new targets" are all those targets that are not "established targets" but which have been or are the subject of drug discovery efforts. The majority of targets selected for drug discovery efforts are proteins, such as G-protein-coupled receptors (GPCRs) and protein kinases.
Following that investigation and one of their own that faulted the university for failing to act on warnings and protect the campus, the university's faculty senate voted "no confidence" in the president and many other leaders at the university. In 2023, the University of Arizona faced a financial crisis, allegedly "losing track of more than $240 million through accounting errors and flawed financial projections." Subsequent investigative reporting by The Arizona Republic linked much of the crisis to the university's purchase of Ashford University, accusing university administrators of knowing that Ashford was experiencing "a downward enrollment spiral that began years before [the purchase] and dismal graduation and retention rates". In April 2024, the UA chapter of Students for Justice in Palestine joined student protests across the USA against the war in Gaza, during what they called "Israeli Apartheid Week". The encampment was attacked and dispersed by police firing rubber bullets, tear gas and pepper balls. Bystanders and press were also hurt in the police violence. The students were protesting against UA involvement with companies supporting the "genocide and ethnic cleansing in Palestine" and called for divestment.
World Refrigeration Day is an international day established by the World Refrigeration Day Secretariat in Derbyshire, England. Held annually on 26 June, it was created to raise awareness about the importance of refrigeration technologies in everyday life and to raise the profile of the refrigeration, air-conditioning and heat-pump sector. The day was chosen to celebrate the birth date of Lord Kelvin on 26 June 1824.
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.